Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 519 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Exercising Safely During Breast Cancer Treatment: What to Know October 27, 2022 FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma August 24, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Amivantamab October 29, 2021 FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer April 14, 2021 Load more HOT NEWS Treating the Whole Person: How Cancer Centers Are Addressing Social Needs Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in... Bra Straps with Disappearing Message Remind Women to Check Their Breasts... FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years...
